Fragment-based drug discovery using the SHAPES method.

about

Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5.Strategies for the design of RNA-binding small molecules.Fragment informatics and computational fragment-based drug design: an overview and update.

P2860

Q36385771-18449027-F104-4C11-89EB-7BB31250C6D2 Q37855857-4F05C8AD-222F-41E5-95B0-59406B817F95 Q37995087-99B4D0D5-EE13-49B6-964E-954819FF08FA

P2860

Fragment-based drug discovery using the SHAPES method.

Item

http://www.wikidata.org/entity/Q38089130

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Fragment-based drug discovery using the SHAPES method.

@en

type

Item

label

Fragment-based drug discovery using the SHAPES method.

@en

prefLabel

Fragment-based drug discovery using the SHAPES method.

@en

P1476

Fragment-based drug discovery using the SHAPES method.

@en

P2093

Christopher Lepre

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery and structure-activity relationship of oxalylarylaminobenzoic acids as inhibitors of protein tyrosine phosphatase 1B

Selective protein tyrosine phosphatase 1B inhibitors: targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands

Fragment screening and assembly: a highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor

MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis

Ligand efficiency: a useful metric for lead selection

Discovering high-affinity ligands for proteins: SAR by NMR

Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water.

Library design for NMR-based screening.

MS/NMR: a structure-based approach for discovering protein ligands and for drug design by coupling size exclusion chromatography, mass spectrometry, and nuclear magnetic resonance spectroscopy.

Drug-like properties and the causes of poor solubility and poor permeability.

P304

1555-1566

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17460441.2.12.1555

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2007-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23488900

http://www.w3.org/2001/XMLSchema#string

Fragment-based drug discovery using the SHAPES method.

about

P2860

P2860

Fragment-based drug discovery using the SHAPES method.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698